Ichor Medical Systems has entered into a product development collaboration and worldwide license agreement with Janssen Pharmaceuticals.
Under the agreement, which was facilitated by Johnson & Johnson Innovation, the parties will work together to develop and commercialize DNA-based vaccine products for the treatment of chronic hepatitis B using Ichor’s TriGrid electroporation technology for clinical administration.
Searching for more deal information? Current Partnering offers the following options:
|
Ichor will receive an upfront payment, R&D support, and development and sales milestone payments up to a potential total of approximately $85 million USD, as well as royalty payments on any future licensed product sales.
Janssen will assume responsibility for certain development costs and all commercialization costs associated with the program, including manufacturing and distribution expense for Ichor’s TriGrid Delivery System.
For further deal information visit Current Agreements (subscription required)
Related
Scorecard: Top partnering deals by value in 2015
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio
